CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

Clinical Trial ID NCT02132624

PubWeight™ 6.92^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02132624

Top papers